Trial Profile
Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy for Intermediate and High-risk Prostate Cancer: a Randomized, Placebo-controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Degarelix
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ARNEO
- 18 Jun 2023 Results (n=88) to exploring the changes in thyroid homeostasis under deep androgen suppression with combined GnRH-antagonist and ARSI presented at the 105th Annual Meeting of the Endocrine Society
- 01 Jun 2023 Primary endpoint (Minimal Residual Disease (MRD)) has been met according to results published in the European Urology
- 01 Jun 2023 Status changed from recruiting to completed according to results published in the European Urology